Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06575075
PHASE1/PHASE2

Pilot Study of RR-HNK in OCD

Sponsor: Carolyn Rodriguez

View on ClinicalTrials.gov

Summary

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Official title: A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2026-01-23

Completion Date

2029-11-30

Last Updated

2026-03-05

Healthy Volunteers

No

Interventions

DRUG

RR-HNK/Hydroxynorketamine

(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.

DRUG

Placebo

Sterile Saline

Locations (1)

Stanford University School of Medicine

Palo Alto, California, United States